Glucocorticoid receptor-targeted liposomal codelivery of lipophilic drug and anti-Hsp90 gene: Strategy to induce drug-sensitivity, EMT-reversal, and reduced malignancy in aggressive tumors

Sujan Kumar Mondal, Sudhakar Jinka, Krishnendu Pal, Swetha Nelli, Shamit Kumar Dutta, Enfeng Wang, Ajaz Ahmad, Khalid M. Alkharfy, Debabrata Mukhopadhyay, Rajkumar Banerjee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Many cancers including the late stage ones become drug-resistant and undergo epithelial-to-mesenchymal transition (EMT). These lead to enhanced invasion, migration, and metastasis toward manifesting its aggressiveness and malignancy. One of the key hallmarks of cancer is its overdependence on glycolysis as its preferred energy metabolism pathway. The strict avoidance of alternate energy pathway gluconeogenesis by cancer cells points to a yet-to-be hoisted role of glucocorticoid receptor (GR) especially in tumor microenvironment, where cells are known to become drug-sensitive through induction of gluconeogenesis. However, since GR is involved in metabolism, anti-inflammatory reactions, immunity besides inducing gluconeogenesis, a greater role of GR in tumor microenvironment is envisaged. We have shown previously that GR, although ubiquitously expressed in all cells; afford to be an effective cytoplasmic target for killing cancer cells selectively. Herein, we report the therapeutic use of a newly developed GR-targeted liposomal concoction (DXE) coformulating a lipophilic drug (ESC8) and an anti-Hsp90 anticancer gene against aggressive tumor models. This induced drug-sensitivity and apoptosis while reversing EMT in tumor cells toward effective retardation of aggressive growth in pancreas and skin tumor models. Additionally, the ESC8-free lipid formulation upon cotreatment with hydrophilic drugs, gemcitabine and doxorubicin, could effectively sensitize and kill pancreatic cancer and melanoma cells, respectively. The formulation-triggered EMT-reversal was GR-dependent. Overall, we found a new strategy for drug sensitization that led to the advent of new GR-targeted anticancer therapeutics.

Original languageEnglish (US)
Pages (from-to)2507-2523
Number of pages17
JournalMolecular Pharmaceutics
Volume13
Issue number7
DOIs
StatePublished - Jul 5 2016

Fingerprint

Epithelial-Mesenchymal Transition
Glucocorticoid Receptors
Pharmaceutical Preparations
Genes
Gluconeogenesis
Neoplasms
Tumor Microenvironment
gemcitabine
Therapeutic Uses
Glycolysis
Pancreatic Neoplasms
Doxorubicin
Energy Metabolism
Pancreas
Immunity
Melanoma
Anti-Inflammatory Agents
Apoptosis
Neoplasm Metastasis
Lipids

Keywords

  • drug-sensitivity
  • EMT
  • glucocorticoid receptor
  • Hsp90
  • liposome
  • tumor

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery

Cite this

Glucocorticoid receptor-targeted liposomal codelivery of lipophilic drug and anti-Hsp90 gene : Strategy to induce drug-sensitivity, EMT-reversal, and reduced malignancy in aggressive tumors. / Mondal, Sujan Kumar; Jinka, Sudhakar; Pal, Krishnendu; Nelli, Swetha; Dutta, Shamit Kumar; Wang, Enfeng; Ahmad, Ajaz; Alkharfy, Khalid M.; Mukhopadhyay, Debabrata; Banerjee, Rajkumar.

In: Molecular Pharmaceutics, Vol. 13, No. 7, 05.07.2016, p. 2507-2523.

Research output: Contribution to journalArticle

Mondal, Sujan Kumar ; Jinka, Sudhakar ; Pal, Krishnendu ; Nelli, Swetha ; Dutta, Shamit Kumar ; Wang, Enfeng ; Ahmad, Ajaz ; Alkharfy, Khalid M. ; Mukhopadhyay, Debabrata ; Banerjee, Rajkumar. / Glucocorticoid receptor-targeted liposomal codelivery of lipophilic drug and anti-Hsp90 gene : Strategy to induce drug-sensitivity, EMT-reversal, and reduced malignancy in aggressive tumors. In: Molecular Pharmaceutics. 2016 ; Vol. 13, No. 7. pp. 2507-2523.
@article{95854bd70eb04b53b677cee79c4dee07,
title = "Glucocorticoid receptor-targeted liposomal codelivery of lipophilic drug and anti-Hsp90 gene: Strategy to induce drug-sensitivity, EMT-reversal, and reduced malignancy in aggressive tumors",
abstract = "Many cancers including the late stage ones become drug-resistant and undergo epithelial-to-mesenchymal transition (EMT). These lead to enhanced invasion, migration, and metastasis toward manifesting its aggressiveness and malignancy. One of the key hallmarks of cancer is its overdependence on glycolysis as its preferred energy metabolism pathway. The strict avoidance of alternate energy pathway gluconeogenesis by cancer cells points to a yet-to-be hoisted role of glucocorticoid receptor (GR) especially in tumor microenvironment, where cells are known to become drug-sensitive through induction of gluconeogenesis. However, since GR is involved in metabolism, anti-inflammatory reactions, immunity besides inducing gluconeogenesis, a greater role of GR in tumor microenvironment is envisaged. We have shown previously that GR, although ubiquitously expressed in all cells; afford to be an effective cytoplasmic target for killing cancer cells selectively. Herein, we report the therapeutic use of a newly developed GR-targeted liposomal concoction (DXE) coformulating a lipophilic drug (ESC8) and an anti-Hsp90 anticancer gene against aggressive tumor models. This induced drug-sensitivity and apoptosis while reversing EMT in tumor cells toward effective retardation of aggressive growth in pancreas and skin tumor models. Additionally, the ESC8-free lipid formulation upon cotreatment with hydrophilic drugs, gemcitabine and doxorubicin, could effectively sensitize and kill pancreatic cancer and melanoma cells, respectively. The formulation-triggered EMT-reversal was GR-dependent. Overall, we found a new strategy for drug sensitization that led to the advent of new GR-targeted anticancer therapeutics.",
keywords = "drug-sensitivity, EMT, glucocorticoid receptor, Hsp90, liposome, tumor",
author = "Mondal, {Sujan Kumar} and Sudhakar Jinka and Krishnendu Pal and Swetha Nelli and Dutta, {Shamit Kumar} and Enfeng Wang and Ajaz Ahmad and Alkharfy, {Khalid M.} and Debabrata Mukhopadhyay and Rajkumar Banerjee",
year = "2016",
month = "7",
day = "5",
doi = "10.1021/acs.molpharmaceut.6b00230",
language = "English (US)",
volume = "13",
pages = "2507--2523",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Glucocorticoid receptor-targeted liposomal codelivery of lipophilic drug and anti-Hsp90 gene

T2 - Strategy to induce drug-sensitivity, EMT-reversal, and reduced malignancy in aggressive tumors

AU - Mondal, Sujan Kumar

AU - Jinka, Sudhakar

AU - Pal, Krishnendu

AU - Nelli, Swetha

AU - Dutta, Shamit Kumar

AU - Wang, Enfeng

AU - Ahmad, Ajaz

AU - Alkharfy, Khalid M.

AU - Mukhopadhyay, Debabrata

AU - Banerjee, Rajkumar

PY - 2016/7/5

Y1 - 2016/7/5

N2 - Many cancers including the late stage ones become drug-resistant and undergo epithelial-to-mesenchymal transition (EMT). These lead to enhanced invasion, migration, and metastasis toward manifesting its aggressiveness and malignancy. One of the key hallmarks of cancer is its overdependence on glycolysis as its preferred energy metabolism pathway. The strict avoidance of alternate energy pathway gluconeogenesis by cancer cells points to a yet-to-be hoisted role of glucocorticoid receptor (GR) especially in tumor microenvironment, where cells are known to become drug-sensitive through induction of gluconeogenesis. However, since GR is involved in metabolism, anti-inflammatory reactions, immunity besides inducing gluconeogenesis, a greater role of GR in tumor microenvironment is envisaged. We have shown previously that GR, although ubiquitously expressed in all cells; afford to be an effective cytoplasmic target for killing cancer cells selectively. Herein, we report the therapeutic use of a newly developed GR-targeted liposomal concoction (DXE) coformulating a lipophilic drug (ESC8) and an anti-Hsp90 anticancer gene against aggressive tumor models. This induced drug-sensitivity and apoptosis while reversing EMT in tumor cells toward effective retardation of aggressive growth in pancreas and skin tumor models. Additionally, the ESC8-free lipid formulation upon cotreatment with hydrophilic drugs, gemcitabine and doxorubicin, could effectively sensitize and kill pancreatic cancer and melanoma cells, respectively. The formulation-triggered EMT-reversal was GR-dependent. Overall, we found a new strategy for drug sensitization that led to the advent of new GR-targeted anticancer therapeutics.

AB - Many cancers including the late stage ones become drug-resistant and undergo epithelial-to-mesenchymal transition (EMT). These lead to enhanced invasion, migration, and metastasis toward manifesting its aggressiveness and malignancy. One of the key hallmarks of cancer is its overdependence on glycolysis as its preferred energy metabolism pathway. The strict avoidance of alternate energy pathway gluconeogenesis by cancer cells points to a yet-to-be hoisted role of glucocorticoid receptor (GR) especially in tumor microenvironment, where cells are known to become drug-sensitive through induction of gluconeogenesis. However, since GR is involved in metabolism, anti-inflammatory reactions, immunity besides inducing gluconeogenesis, a greater role of GR in tumor microenvironment is envisaged. We have shown previously that GR, although ubiquitously expressed in all cells; afford to be an effective cytoplasmic target for killing cancer cells selectively. Herein, we report the therapeutic use of a newly developed GR-targeted liposomal concoction (DXE) coformulating a lipophilic drug (ESC8) and an anti-Hsp90 anticancer gene against aggressive tumor models. This induced drug-sensitivity and apoptosis while reversing EMT in tumor cells toward effective retardation of aggressive growth in pancreas and skin tumor models. Additionally, the ESC8-free lipid formulation upon cotreatment with hydrophilic drugs, gemcitabine and doxorubicin, could effectively sensitize and kill pancreatic cancer and melanoma cells, respectively. The formulation-triggered EMT-reversal was GR-dependent. Overall, we found a new strategy for drug sensitization that led to the advent of new GR-targeted anticancer therapeutics.

KW - drug-sensitivity

KW - EMT

KW - glucocorticoid receptor

KW - Hsp90

KW - liposome

KW - tumor

UR - http://www.scopus.com/inward/record.url?scp=84979036965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979036965&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.6b00230

DO - 10.1021/acs.molpharmaceut.6b00230

M3 - Article

C2 - 27184196

AN - SCOPUS:84979036965

VL - 13

SP - 2507

EP - 2523

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 7

ER -